| Compound | PE-22-28 |
|---|---|
| Category | Trefoil factor-derived peptide |
| Class | Neuro, Nootropic, and Cosmetic Peptides |
| Evidence tier | Preclinical |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
PE-22-28 — a trefoil factor-derived peptide — sits in the "Preclinical" tier of this catalog. The evidence base for this compound is dominated by animal and cell-culture studies. Mechanism may be plausible; human benefit and safety are unestablished.
A peptide derived from trefoil factor 2, studied in animal models for antidepressant-like effects and neurogenesis.
Mechanism of Action
Reported to influence hippocampal neurogenesis and depressive-like behavior in rodents via trefoil-factor signaling.
Research and Evidence
Preclinical only; no human studies.
Safety and Side Effects
No human safety data.
Frequently Asked Questions
What is the evidence tier of PE-22-28?
PE-22-28 is graded "Preclinical" on this site. The evidence base for this compound is dominated by animal and cell-culture studies. Mechanism may be plausible; human benefit and safety are unestablished.
Is PE-22-28 an approved medicine?
No. Preclinical means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for PE-22-28?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — search for PE-22-28 studies (none registered). [source]
Evidence tier: Preclinical · Last reviewed: 2026-09-05 · Sources cited below.